オハイオ州立大学脳神経外科のNakano Lab（腫瘍幹細胞研究）では、ポスドクを募集します。当研究室はUCLA脳神経外科において2006年に立ち上げ、2009年9月からOSUに移りました。仕事内容は、脳腫瘍の幹細胞性を維持するメカニズム解析、動物モデルを用いた治療法開発です。トレーニングを受けるフェローには、全米、アジア、欧州にまたがって２０を超える共同研究先とのプロジェクトの一部を自ら主導していただきます。コラボレーション先は最近の論文を参照してください。

＜募集要件＞
ポスドク資格：PhD or MD/PhD
生化学と分子生物学の実験手技を有する方（PCR, cloning, Western blot, IHC, ICC, cell culture, cDNA microarray, RNA/DNA handling 等）。in vivoの実験（transplantation, ventricular injection, in utero injection, gene targeting等）が出来る方。ただ、技術より情熱と協調性を重要視します。米国でいずれ自らのラボを独立する夢を目指す方を探しています。

＜期間＞
2014年夏以降　2-3年間。３ヶ月ごとに契約内容を見直し、１年ごとに更新。

＜募集人数＞
３名募集。米国内からの候補者は現在インタビューを継続しております。

＜給与＞
各候補者の経験、NIH指導要綱をもとに決定します。

＜グラント＞
1) R01 NS083767 (P.I.: Ichiro Nakano), 7/1/2013-6/30/2018, $1,288,550.00
2) R01 NS087913 (multi P.I.: Ichiro Nakano and Jeremy Rich), 4/15/2014-2/28/2019, $2,024,796.00
3) R21CA175875 (P.I.: Nakano, I), 1/1/2014-12/31/2015, $376,620.00
4) P01 CA163205-01A1 (overall P.I.: Antonio Chiocca and Ichiro Nakano as PI for Glioma Biorepository Core), 4/1/2013-3/31/2018, $10,463.675.00
5) R01 NS (P.I.: Lathia, J and Ichiro Nakano as co-Investigator), 7/1/2013-6/30/2018

＜提出書類＞
CV(English), 3 references, 1 page proposal

＜問い合わせ先＞
Ichiro Nakano, M.D., Ph.D.
Associate Professor,
Director, Brain Cancer Stem Cell Program,
The Khan Foundation Clinical Investigator,
Departments of Neurological Surgery,
Ohio State University
e-mail: ichiro.nakano@osumc.edu

＜参考文献（２０１３年以降）＞
35. Tumor-specific activation of the c-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner. Gu C, Banasavadi-Siddegowda YK, Joshi K, Nakamura Y, Kurt H, Gupta S, and Nakano I. Stem Cells 2013 Jan 17. doi: 10.1002/stem.1322.

36. MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. Joshi K, Banasavadi-Siddegowda Y, Mo X, Kim S, Mao P, Kig C, Nardini D, Sobol RW, Chow L, Kornblum HI, Waclaw R, Beullens M, and Nakano I. Stem Cells 2013 Feb 13. doi: 10.1002/stem.1358.

37. Fluorescence-Guided Brain Tumor Surgery. Smith L and Nakano I. World Neurosurgery 2012 Dec;78(6):559-64. doi: 10.1016/j.wneu.2012.10.015. Epub 2012 Oct 4

38. Phosphorylation of a Polycomb component EZH2 by AKT activates STAT3 and promotes self-renewal and tumorigenicity of glioblastoma stem-like cells. Kim E, Kim M, ShinY, Joo KM, Woo DH, Chang N, Oh Y, Rheey J, Nakano I, Rich JN, Nam DH, Lee J. Cancer Cell 2013 Jun 10;23(6):839-52. doi: 10.1016/j.ccr.2013.04.008. Epub 2013 May 16.

39. MicroRNA-128 coordinately targets Polycomb Repressor Complexes in glioma stem cells. Peruzzi P, Bronisz A, Nowicki MC, Wang Y, Ogawa D, Price R, Nakano I, Kwon CH, Hayes J, Lawler SE, Ostrowski MC, Chiocca EA, Godlewski J. Neuro-oncology 2013 Sep;15(9):1212-24. doi: 10.1093/neuonc/not055. Epub 2013 Jun 3.

40. Mesenchymal Glioma Stem Cells are Maintained by Activated Glycolytic Metabolism Involving Aldehyde Dehydrogenase 1A3. Mao P, Kim SH, Li J, Joshi K, Li PP, Santana-Santos L, Luthra S, Chandran UR, Benos PV, Smith L, Wang MD, Hu B, Cheng SY, Sobol RW, Nakano I. Proc Natl Acad Sci U S A. 2013 May 21;110(21):8644-9. doi: 10.1073/pnas.1221478110. Epub 2013 May 6. (selected as Research Highlights by the Association of American Cancer Institutes)

41. Mesenchymal Differentiation Mediated by NFB Promotes Radiation Resistance in Glioblastoma. Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James JD, Goodman LD, Conroy S, Long L, Lelic N, Wang S, Gumin J, Raj D, Kodama Y, Raghunathan A, Olar A, Joshi K, Pelloski CE, Heimberger A, Kim SH, Cahill DP, Rao G, denDunnen WFA, Boddeke HWGM, Phillips HS, Nakano I, Lang FF, Colman H, Sulman EP, and Aldape K. Cancer Cell 2013 Sep 9;24(3):331-46. doi: 10.1016/j.ccr.2013.08.001. Epub 2013 Aug 29.

42. Brain Tumor Initiating Cells Adapt to Restricted Nutrition through Preferential Glucose Uptake. Flavahan W, Wu Q, Hitomi M, Rahim N, Kim Y, Sloan AE, Weil RJ, Nakano I, Sarkaria JN, Stringer BW, Li M, Lathia JD, Rich JN, Hjelmeland AB. Nature Neuroscience 2013 Oct;16(10):1373-82. doi: 10.1038/nn.3510. Epub 2013 Sep 1.

43. miR-21 in the Extracellular Vesicles (EVs) of Cerebrospinal Fluid (CSF): A Platform for Glioblastoma Biomarker Development. Akers JC, Ramakrishnan V, Kim R, Skog J, Nakano I, Pingle S, Kalinina J, Hua W, Kesari S, Mao Y, Breakefield XO, Hochberg FH, Van Meir EG, Carter BS, Chen CC. PLoS One. 2013 Oct 21;8(10):e78115. doi: 10.1371/journal.pone.0078115.

44. High-throughput analysis of miR-137 in glioblastoma reveals a complex network of targets associated with malignant transformation and neuronal differentiation. Tamim S, Vo DT, Uren P, Qiao M, Smith AD, Nakano I, Kuersten S, Penalva LO. PLoS ONE 2014 Jan 22;9(1):e85591. doi: 10.1371/journal.pone.0085591.

45. Extracellular vesicles modulate the glioblastoma microenvironment via a tumor suppression signaling network directed by miR-1. Bronisz A, Wang Y, Nowicki MO, Peruzzi P, Ansari K, Ogawa D, Balaj L, Derienzo G, Mineo M, Nakano I, Ostrowski MC, Hochberg F, Weissleder R, Lawler SE, Chiocca EA, Godlewski J. Cancer Res. 2014 Feb 1;74(3):738-50. doi: 10.1158/0008-5472.CAN-13-2650.

46. Multi-kinase inhibitor C1 triggers mitotic catastrophe of glioma stem cells mainly through MELK kinase inhibition. Minata M, Gu C, Joshi K, Nakano-Okuno M, Hong C, Nguyen CH, Kornblum HI, Molla A, Nakano I. PLoS ONE [in press]

47. Maintenance of the glioblastoma cellular hierarchy is regulated by junctional adhesion molecule-A. Lathia JD, Li M, Sathyan P, Hale J, Zinn P, Gallagher J, Wu Q, Sinyuk M, Nakano I, McLendon RE, Sloan AE, Carson C, Naik U, Hjelmeland AB, Majumder S, Rich JN, Cell Reports 2014 Jan 16;6(1):117-29. doi: 10.1016/j.celrep.2013.11.043

48. The AMPK inhibitor Compound C is a potent AMPK-independent anti-glioma agent. Xiaona Liu X, Chhipa RR, Nakano I, and Dasgupta B. Mol Cancer Ther 2014 Mar;13(3):596-605. doi: 10.1158/1535-7163.MCT-13-0579.

49. ID4-driven suppression of miR129 regulates the PDGFRα-NO-ID4 signaling circuit and Notch activity in glioma stem cells and endothelium. Jeon HM, Kim SH, Park JB, Kim SH, Nakano I, Kim H. Cancer Research [in press]

50. Engulfing Losers by Winners in Cancer: Do Cancer Stem Cells Catch Eat-Me Signals from non-Stem Cancer Cells? (Editorial) Nakano I. Future Oncology [in press]

51. Maternal Embryonic Leucine-zipper Kinase: Major Kinase for Glioma and other Cancer Stem Cells. Ganguly R, Hong C, Smith L, Kornblum HI, and Nakano I. Mol Cancer Ther [in press]

52. Proneural-Mesenchymal Transformation of Glioma Stem Cells: Therapies cause evolution of target in glioblastoma? (Editorial) Nakano I. Future Oncology [in press]

53. Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells. Kim TH, Song J, Kim SH, Parikh AK, Xiaokui M, Palanichamy K, Kaur B, Yu J, Yoon SO, Nakano I, and Kwon CH. Neuro-oncology [in press]